Search research articles
Contact Us
Filters
Showing results (131-140 of 148) with videos related to
Page
of 15
Sort By:
NCI Monographs : a Publication of the National Cancer Institute
|
January 1, 1987
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717)
A H Calvert, D R Newell, A L Jackman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1986
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717
A H Calvert, D L Alison, S J Harland, et al.
Journal of Medicinal Chemistry
|
March 17, 1995
Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series
P R Marsham, A L Jackman, A J Barker, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 31, 2000
Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP)
H C Barlow, K J Bowman, N J Curtin, et al.
Journal of Medicinal Chemistry
|
November 1, 1990
Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position
L R Hughes, A L Jackman, J Oldfield, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1993
Advanced epithelial ovarian cancer: 1993 consensus statements
D G Allen, J Baak, D Belpomme, et al.
British Journal of Cancer
|
March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
A Azzabi, A N Hughes, P M Calvert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors
I Rafi, A V Boddy, J A Calvete, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2002
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules
A B Simpson, P M Calvert, J A Sludden, et al.
Journal of Medicinal Chemistry
|
November 7, 2000
Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine
R J Griffin, C E Arris, C Bleasdale, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 148) with videos related to
Sort By:
Page
of 15
NCI Monographs : a Publication of the National Cancer Institute
|
January 1, 1987
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717)
A H Calvert, D R Newell, A L Jackman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1986
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717
A H Calvert, D L Alison, S J Harland, et al.
Journal of Medicinal Chemistry
|
March 17, 1995
Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series
P R Marsham, A L Jackman, A J Barker, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 31, 2000
Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP)
H C Barlow, K J Bowman, N J Curtin, et al.
Journal of Medicinal Chemistry
|
November 1, 1990
Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position
L R Hughes, A L Jackman, J Oldfield, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1993
Advanced epithelial ovarian cancer: 1993 consensus statements
D G Allen, J Baak, D Belpomme, et al.
British Journal of Cancer
|
March 10, 2005
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
A Azzabi, A N Hughes, P M Calvert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors
I Rafi, A V Boddy, J A Calvete, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 9, 2002
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules
A B Simpson, P M Calvert, J A Sludden, et al.
Journal of Medicinal Chemistry
|
November 7, 2000
Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine
R J Griffin, C E Arris, C Bleasdale, et al.
Page
of 15